↓ Skip to main content

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Overview of attention for article published in Frontiers in oncology, February 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
1 news outlet
twitter
3 X users

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
Published in
Frontiers in oncology, February 2023
DOI 10.3389/fonc.2023.1128569
Pubmed ID
Authors

Y. Linda Wu, Grace van Hyfte, Umut Özbek, Marlene Reincke, Anuhya Gampa, Yehia I. Mohamed, Naoshi Nishida, Brooke Wietharn, Suneetha Amara, Pei-Chang Lee, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Arndt Vogel, Arndt Weinmann, Anwaar Saeed, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Mahvish Muzaffar, Yi-Hsiang Huang, Ahmed O. Kaseb, Masatoshi Kudo, David J. Pinato, Celina Ang

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 15%
Student > Master 2 15%
Student > Bachelor 1 8%
Student > Postgraduate 1 8%
Unspecified 1 8%
Other 0 0%
Unknown 6 46%
Readers by discipline Count As %
Medicine and Dentistry 2 15%
Unspecified 1 8%
Biochemistry, Genetics and Molecular Biology 1 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Immunology and Microbiology 1 8%
Other 1 8%
Unknown 6 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2023.
All research outputs
#3,767,590
of 26,411,386 outputs
Outputs from Frontiers in oncology
#1,221
of 23,405 outputs
Outputs of similar age
#80,403
of 510,670 outputs
Outputs of similar age from Frontiers in oncology
#38
of 1,485 outputs
Altmetric has tracked 26,411,386 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,405 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 510,670 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 1,485 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.